Business Wire

Carbios Doubles Its Number of Granted Patents in Two Years for Its Proprietary Enzymatic Technologies

1.3.2023 12:02:00 EET | Business Wire | Press release

Share

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228006180/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Carbios patent tiles by geographic region (Graphic: Carbios)

Carbios (Euronext Growth Paris: ALCRB) (Paris:ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastics and textiles, has doubled its number of issued patents since the last review published at the end of 20201.

Protection of Carbios’ processes

Carbios (and its subsidiary Carbiolice) currently holds 336 titles worldwide divided into 53 patent families. In 2022, several titles protecting the proprietary PET-degrading enzymes were granted in countries of interest such as the United States and also in Asian countries including Indonesia, South Korea, China, Japan and India. Carbios has also obtained grants within its patent families protecting the biodegradable plastics production process, notably the masterbatch containing the enzyme or its production process.

"Over the past two years, we have mainly focused on strengthening the protection of our PET biorecycling process and its proprietary enzymes," commented Lise LUCCHESI, Director of Intellectual Property at Carbios . "For the coming years, we will continue to consolidate the protection of this process, and that of our PLA biodegradation process, by filing new patent applications. We will also actively follow up on our filed patent applications in order to obtain granted patents."

"Since the beginning of Carbios, the R&D and Intellectual Property departments have worked hand in hand to ensure maximum protection of our enzymes and processes," commented Alain Marty, Chief Scientific Officer at Carbios. "These continued efforts to obtain extensive international protection are crucial to safeguard our innovations and ensure the industrial deployment of our technologies."

Worldwide protection

Carbios is expanding its intellectual property portfolio in regions and countries where there is strong demand for its disruptive technologies (see Fig. 1), notably :

  • in Europe: 40 European titles, which could be granted in the 39 member states of the European Patent Organization
  • in North America: 41 titles in the United States and 23 in Canada
  • in Asia: 152 titles, including 37 in China, 27 in Japan and 24 in India

Carbios also has 14 patent applications that may be extended to other countries or regions of the world in the coming years.

"We are convinced that biological recycling is the most efficient and circular solution to degrade plastics," stated Emmanuel LADENT, CEO of Carbios . "The protection of our enzymes and processes is at the heart of our work, and we have a dedicated Intellectual Property team within Carbios. From 2023, we will also focus our efforts on protecting innovation related to enzymatic degradation of other polymers."

A dedicated Intellectual Property team

The Intellectual Property team at Carbios includes a Director (who is also a member of the Executive Committee) and two patent engineers specialized in the fields of biotechnology and polymer chemistry, one of whom is a representative before the European Patent Office. The team is supported by two external Intellectual Property consulting firms (Becker & Associés and Franck Tetaz Intellectual Property). Finally, an Intellectual Property Committee reports regularly to Carbios’ Board of Directors.

About Carbios

Established in 2011 by Truffle Capital, Carbios is a green biotech company, developing biological and innovative processes. Through its unique approach of combining enzymes and plastics, Carbios aims to address new consumer expectations and the challenges of a broad ecological transition by taking up a major challenge of our time: plastic and textile pollution. Carbios deconstructs any type of PET (the dominant polymer in bottles, trays, textiles made of polyester) into its basic components which can then be reused to produce new PET plastics with equivalent quality to virgin ones. This PET innovation, the first of its kind in the world, was recently recognized in a scientific paper published in front cover of the prestigious journal Nature. Carbios successfully started up its demonstration plant in Clermont-Ferrand in 2021. It has now taken another key step towards the industrialization of its process with the construction of a first-of-a-kind unit in partnership with Indorama Ventures.

In 2017, Carbios and L’Oréal co-founded a consortium to contribute to the industrialization of its proprietary recycling technology. Committed to developing innovative solutions for sustainable development, Nestlé Waters, PepsiCo and Suntory Beverage & Food Europe joined this consortium in April 2019. In 2022, Carbios signed an agreement with On, Patagonia, PUMA, and Salomon, to develop solutions promoting the recyclability and circularity of their products. PVH Corp. joined this consortium in January 2023.

The Company has also developed an enzymatic biodegradation technology for PLA-based (a bio sourced polymer) single-use plastics. This technology can create a new generation of plastics that are 100% compostable at ambient temperatures, even in domestic conditions, integrating enzymes at the heart of the plastic product.

For more information, please visit carbios.com / Twitter: Carbios / LinkedIn: Carbios / Instagram: insidecarbios

Carbios (ISIN FR0011648716/ALCRB) is eligible for the PEA-PME, a government program allowing French residents investing in SMEs to benefit from income tax rebates.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in France, in Europe, in the United States or in any other country.

In case of discrepancy between the French and the English version of this press release, the French version shall prevail.

1 Cf. press release dated 14 January 2021

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

CARBIOS
Melissa Flauraud
Press Relations
melissa.flauraud@carbios.com
Benjamin Audebert
Investor Relations
contact@carbios.com
+33 (0)4 73 86 51 76

Press Relations (France)
Iconic
Marie-Virginie Klein
mvk@iconic-conseil.com
+33 (0)1 44 14 99 96

Press Relations (U.S.)
Rooney Partners
Kate L. Barrette
kbarrette@rooneyco.com
+1 212 223 0561

Press Relations (DACH & UK)
MC Services
Anne Hennecke
carbios@mc-services.eu
+49 (0)211 529 252 22

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hologic Signs Definitive Agreement to Acquire Reveal Genomics19.10.2026 22:30:00 EEST | Press release

Hologic, a global leader in women’s health, today announced that it has signed a definitive agreement to acquire Reveal Genomics, a precision oncology company based in Barcelona, Spain, that develops advanced genomic diagnostic tests to help personalized cancer treatment, including its HER2DX test to help optimize therapy for patients with HER2-positive breast cancer. Breast cancer remains one of the most significant health challenges women face today. Reveal Genomics’ tests are highly complementary to Hologic’s existing oncology diagnostics, including the Breast Cancer Index® (BCI) test, the guideline-recognized genomic assay to help inform decisions regarding extended endocrine therapy in women with HR+ early-stage breast cancer. The combination of Hologic’s existing testing with Reveal Genomics’ portfolio represents a significant expansion of Hologic’s diagnostic oncology solutions, with the combined offering of new and existing testing expected to help inform treatment decisions fo

An Active Role in Freshness: ProAmpac Introduces ProActive Intelligence Shelf Protect19.10.2026 22:27:00 EEST | Press release

ProAmpac, a global leader in flexible packaging and material science, introduces ProActive Intelligence™ Shelf Protect (SP) Series, giving food producers a new way to help preserve product quality and reduce costly spoilage. Designed for select meat, seafood, and dairy applications, the technology is FDA- and USDA-compliant for intended uses in fresh beef, fresh pork, cooked sausage, deli meat, fresh salmon, and fresh cheese. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019305953/en/ Clearshield®-SP Shrink Bag This direct food-contact biotechnology packaging helps reduce microbial growth associated with food spoilage in intended applications, supporting longer shelf life throughout storage and distribution. Shelf Protect’s patented biotechnology is built directly into food-contact packaging film. “For meat processors, every product lost represents an investment in production, packaging, and distribution that goes unreal

Vedanta Ltd Doubles Zinc Capacity in South Africa with US$ 600 Mn investment19.10.2026 20:19:00 EEST | Press release

Vedanta Limited doubled its annual zinc production capacity to 500,000 tonnes1in South Africa through an investment of nearly US$ 600 Mn at Gamsberg (Phase II) at Vedanta Zinc International (VZI). Gamsberg has one of the world’s most significant zinc deposits and is VZI’s flagship zinc mine. Inaugurated by South African President Cyril Ramaphosa and Vedanta Limited Director Priya Agarwal-Hebbar, this expansion marks one of the decade’s largest mining investments in South Africa. It advances Vedanta Limited’s position as the world’s largest2 zinc producer, with a vision of achieving 3 million tonnes of annual production across India and South Africa. Of this, 2 million tonnes are targeted from its subsidiary, Hindustan Zinc Limited the world’s largest integrated zinc producer, while Vedanta Zinc International business aims to contribute 1 million tonnes annually. This expansion strengthens the ZAR 21 Bn (nearly US$ 1.5 Bn) investment commitment Vedanta made at the 2018 South Africa Inve

Unlocking Digital Gold’s US$700bn Opportunity19.10.2026 19:00:00 EEST | Press release

The digital gold market, worth US$45–55bn today, could unlock up to US$700bn in latent demand, according to new research from World Gold Council and Boston Consulting Group. The report points to substantial untapped appetite among retail investors, with nearly nine in ten surveyed saying they would consider digital gold under the right conditions. The US$700bn opportunity represents the report’s estimate of total latent demand that could be released if today’s barriers to adoption were removed, rather than a near-term forecast. The report’s five-year base case sees digital gold growing by around 27% a year to US$160–170bn by 2031. That could rise to US$270–280bn over the same time if more barriers fall faster. Momentum is already building as financial markets undergo a broader digital transformation, bringing tokenised investment products increasingly into the mainstream. Tokenised gold, one segment of the digital gold market alongside vaulted digital gold, has grown fivefold in value

Roquette Brings Broad Portfolio of Excipient Solutions and Technical Expertise to AAPS PharmSci 360 202619.10.2026 17:00:00 EEST | Press release

Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, will showcase its expansive portfolio of excipients, capsules, coatings, and biopharma solutions at AAPS PharmSci 360 2026. The conference and trade show will take place October 26-28 in New Orleans, Louisiana, USA. At Booth 1100 in the exhibit hall, Roquette’s Health & Pharma Solutions team will share their expertise across controlled-release technologies, hydroxypropyl beta-cyclodextrins, and sustainable formulation approaches, alongside a comprehensive portfolio of innovative solutions designed to address the evolving needs of pharmaceutical developers. “AAPS PharmSci 360 is a key opportunity to share our latest innovations, as well as highlight the breadth and depth of our scientific know-how that helps our customers solve complex formulation challenges,” said Peter Freed, Head of Technical Service & Development North America for Roquette’s Health & Pharma Solutions Business Unit. “From a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye